Marketed By
bdr pharma
Pack of
60 Tablets in Bottle
Salt Composition
Rucaparib
Storage
Keep in Cold Place
₹32650₹42187.50
22.61% Off
Tax: ₹3918
1
Bdparib 200mg Tablet
Delivering To: —
All Substitutes
Overview
The Bdparib 200 mg is a member of the class known as polyADP-ribose polymerase inhibitors. The active component of this anti-cancer medication is rucaparib. It is used to treat some forms of ovarian cancer, fallopian tube cancer (found in females), and primary peritoneal cancer (a layer of tissue lining the belly). In individuals with a certain gene mutation (BRCA), the bdparib 200mg is also used to treat some forms of cancer. Those who are allergic to Bdparib or any of its constituents should not take this cancer medication.
Indication
Ovarian Cancer, Prostate cancer
Uses
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
Benefits
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
Side Effects
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
How To Use
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
How It Works
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
Safety Advice
Alcohol
consult your doctor
Drinking too much alcohol could damage a person's immunity and liver function. Alcohol consumption can cause dizziness, confusion, tiredness, and cognitive impairment, so it is advised not to consume alcohol while taking the Bdparib 200mg tablet.
Pregnancy
consult your doctor
It is not advised to take the Bdparib 200mg tablet when pregnant because it affects the fetus. This is not for use in pregnant women.
Breast Feeding
consult your doctor
Because there is a possibility that the Bdparib 200mg tablet could be transferred to the developing infant through the mother's breast milk, it is not advised to consume it while nursing. It is widely regarded as dangerous, and there is not enough evidence in the clinical data on its adverse impacts on infants.
Driving
unsafe
Taking a Bdparib 200mg tablet while operating machinery may cause confusion or impair one's driving capacity. The capsule may cause neurological side effects, such as fever or feeling dizzy. Until you feel better, don't drive.
Kidney
safe if prescribed
People with kidney issues can use the Bdparib 200mg tablet after consulting with the doctor. It may harm the kidneys if taken as self-medication.
Liver
safe if prescribed
People with severe liver illness should not use the Bdparib 200mg tablet. Whereas people with mild liver disease can use this solution, but it must be regularly monitored. Use caution and alter the dosage of the Bdparib 200mg tablet as advised by your doctor.
Missed Doses
Quick Tips
FAQs
As soon as you remember, take the missed dose unless it's time for your next dose. You should never take a double dose to make up for a missed one.
Common side effects of the Bdparib 200mg tablet are constipation, muscle pain, swelling, nausea, diarrhea, infection, loss of appetite, hair loss, vomiting, and weakness.
The doctor decides how long the treatment with the Bdparib 200mg tablet will continue, depending on the stage and health of the patient.
It is advised not to take alcohol while taking the Bdparib 200mg tablet, because consuming alcohol can cause serious side effects and can damage your liver badly. Consult your doctor if you have concerns or queries.
During pregnancy, it is not safe to take the Bdparib 200mg tablet, as it can cause harm to the unborn baby. Furthermore, during breastfeeding, this medicine must not be used. Please make sure to consult your healthcare provider regarding the same.
Bdparib 200 mg tablet blocks the androgen receptor due to the presence of enzalutamide. It blocks testosterone from reaching prostate cancer cells. Testosterone production helps cancer cells grow, so by blocking the generation of this hormone, the growth of cancer cells can be shrunk. Bdparib 200 mg tablet belongs to the androgen receptor inhibitors.
Inform the doctor if you are allergic to the ingredient present in the Bdparib 200 mg tablet, in case of high sugar level, pregnancy or breastfeeding, or a weakened immune system. A patient with a medical history or medication must discuss it with a doctor.
No, Bdparib 200mg tablet is an anti-cancer medication that contains enzalutamide, which is an androgen receptor inhibitor.
Bdparib 200 mg tablet blocks the androgen receptor due to the presence of enzalutamide. It blocks testosterone from reaching prostate cancer cells. Testosterone production helps cancer cells grow, so blocking its production can shrink cancer cell growth. Bdparib 200 mg belongs to the androgen receptor inhibitors.
Reference
Bixel, K., & Hays, J. L. (2025). Olaparib in the management of ovarian cancer. Pharmacogenomics and personalized medicine, 127-135.
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., & Carmichael, J. (2023). Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research, 15(5), R88.
Luvero, D., Milani, A., & Ledermann, J. A. (2024). Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Therapeutic advances in medical oncology, 6(5), 229-239.
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., & Molife, L. R. (2022). An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Targeted oncology, 11(3), 401-415.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2025). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.
Ratings And Reviews
4.67/5
3 Ratings
5 Star
66.67%
4 Star
33.33%
3 Star
0.00%
2 Star
0.00%
1 Star
0.00%
a year ago
10 months ago
View All Reviews
Related Products
MARKETER DETAILS
bdr pharma
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.